单位：[1]Department of International MedicalCenter, Beijing Friendship Hospital, CapitalMedical University, Beijing, China首都医科大学附属北京友谊医院[2]Department of Endocrinology, BeijingTiantan Hospital, Capital Medical University,Beijing, China首都医科大学附属天坛医院
Background and objectives Metabolic syndrome (MetS) is an independent risk factor for cardiovascular disease (CVD), in which platelet hyperactivation plays a pivotal role. The purpose of this study was to evaluate platelet function in MetS patients using Platelet Function Analyzer-100 (PFA-100) and to explore the risk factors for platelet hyperactivity in MetS. Subjects and methods We investigated participants who were enrolled for health check-up in our department. Routine physical examinations and fasting blood sample tests were performed when participants visited the hospital. MetS was defined as >= 3 of the risk factors according to the Harmonised criteria: central obesity, hypertension (HP), hypertriglyceridemia, low high density lipoprotein cholesterol and hyperglycaemia. Participants were divided into a MetS group (>= 3), normal control (NC) group (0) and non-MetS group (1-2) according to the numbers of the five risk factors. Platelet function was tested by PFA-100, which measures the time taken for blood to occlude an aperture (closure time [CT]). All continuous data were compared using Student's t test or Mann-Whitney U test according to the data distribution. Categorical data were compared using the chi-square test. Logistic regression was used to investigate the independent risk marker for PFA-100 CT values. Results A total of 831 participants (611 males and 220 females) was included in our subject. The MetS group had significantly shorter CT values compared with the NC group (106 (52-181) s vs 111 (70-210) s, P < .05) and the non-MetS Group (106 (52-181) s vs 113 (73-197) s, P < .05). Higher body mass index, hypertriglyceridemia and HP were correlated with shorter CT values (P < .05). Logistic regression analyses indicated that hypertriglyceridemia was an independent risk marker for shorter PFA-100 CT values (P < .05). Conclusion Our results indicate the presence of platelet hyperactivation in MetS patients and that hypertriglyceridemia is an independent risk marker for it. Triglyceride-lowering treatment may reduce CVD risk in MetS individuals.
基金：
"215" High Level Health Technology Talents Training Plan [2015-3-006]
第一作者单位：[1]Department of International MedicalCenter, Beijing Friendship Hospital, CapitalMedical University, Beijing, China
通讯作者：
通讯机构：[1]Department of International MedicalCenter, Beijing Friendship Hospital, CapitalMedical University, Beijing, China[*1]Department of International Medical Center, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xicheng Qu, Beijing 100050, China.
推荐引用方式(GB/T 7714)：
Wang Tingting,Xu Jian,Fu Li,et al.Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients[J].INTERNATIONAL JOURNAL of CLINICAL PRACTICE.2020,74(7):doi:10.1111/ijcp.13508.
APA：
Wang, Tingting,Xu, Jian,Fu, Li&Li, Li.(2020).Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients.INTERNATIONAL JOURNAL of CLINICAL PRACTICE,74,(7)
MLA：
Wang, Tingting,et al."Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients".INTERNATIONAL JOURNAL of CLINICAL PRACTICE 74..7(2020)
